Effects of Switching from Semaglutide 1.0 mg to Tirzepatide on Body Weight and HbA1c: A Retrospective Observational Study

Effects of Switching from Semaglutide 1.0 mg to Tirzepatide on Body Weight and HbA1c: A Retrospective Observational Study - Effects of Switching from Semaglutide 1.0 mg to Tirzepatide on Body Weight and HbA1c

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000057510

Enrollment

Registered

2025-04-04

Start date

2023-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Diagnosed with type 2 diabetes mellitus Switched from semaglutide 1.0 mg to tirzepatide (7.5 mg or 10 mg) Body weight and HbA1c data available before and after tirzepatide initiation Received tirzepatide treatment for at least 3 months

Exclusion criteria

Exclusion criteria: Patients who were treated with other GLP-1 receptor agonists concurrently Patients who discontinued tirzepatide within 3 months Patients with missing data on key endpoints (body weight or HbA1c)

Design outcomes

Primary

Measure	Time frame
Change in body weight (after 3 months), Change in HbA1c (after 3 months)	—

Countries

Japan

Contacts

Public ContactNOBORU KURINAMI

Jinnouchi Hospital Internal Medicine

kurinami@jinnouchi.or.jp0963630011

Outcome results